Neurocrine Biosciences, Inc. (NBIX)
153.04
+0.47
(+0.31%)
USD |
NASDAQ |
Aug 24, 16:00
153.04
0.00 (0.00%)
After-Hours: 18:24
Neurocrine Biosciences Price to Book Value : 4.210 for Aug. 24, 2026
Price to Book Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Price to Book Value Data
| Date | Value |
|---|---|
| August 21, 2026 | 4.197 |
| August 20, 2026 | 4.207 |
| August 19, 2026 | 4.278 |
| August 18, 2026 | 4.242 |
| August 17, 2026 | 4.250 |
| August 14, 2026 | 4.201 |
| August 13, 2026 | 4.149 |
| August 12, 2026 | 4.305 |
| August 11, 2026 | 4.454 |
| August 10, 2026 | 4.536 |
| August 07, 2026 | 4.495 |
| August 06, 2026 | 4.396 |
| August 05, 2026 | 4.442 |
| August 04, 2026 | 4.568 |
| August 03, 2026 | 4.572 |
| July 31, 2026 | 4.588 |
| July 30, 2026 | 5.103 |
| July 29, 2026 | 4.973 |
| July 28, 2026 | 5.029 |
| July 27, 2026 | 4.852 |
| July 24, 2026 | 4.835 |
| July 23, 2026 | 4.790 |
| July 22, 2026 | 4.750 |
| July 21, 2026 | 4.925 |
| July 20, 2026 | 4.759 |
| Date | Value |
|---|---|
| July 17, 2026 | 4.700 |
| July 16, 2026 | 4.719 |
| July 15, 2026 | 4.733 |
| July 14, 2026 | 4.732 |
| July 13, 2026 | 4.789 |
| July 10, 2026 | 4.872 |
| July 09, 2026 | 4.966 |
| July 08, 2026 | 4.903 |
| July 07, 2026 | 4.882 |
| July 06, 2026 | 4.789 |
| July 02, 2026 | 4.793 |
| July 01, 2026 | 4.615 |
| June 30, 2026 | 4.636 |
| June 29, 2026 | 5.019 |
| June 26, 2026 | 4.975 |
| June 25, 2026 | 4.847 |
| June 24, 2026 | 4.903 |
| June 23, 2026 | 4.766 |
| June 22, 2026 | 4.772 |
| June 18, 2026 | 4.673 |
| June 17, 2026 | 4.694 |
| June 16, 2026 | 4.618 |
| June 15, 2026 | 4.709 |
| June 12, 2026 | 4.717 |
| June 11, 2026 | 4.804 |
Price to Book Ratio Definition
Price to book value is a valuation ratio that is measured by stock price / book value per share. The book value is essentially the tangible accounting value of a firm compared to the market value that is shown.
Price to Book Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Price to Book Value Benchmarks
| Amarin Corp. Plc | 0.6543 |
| Liquidia Corp. | 32.09 |
| Incyte Corp. | 4.054 |
| Krystal Biotech, Inc. | 7.442 |
| Halozyme Therapeutics, Inc. | 86.31 |
Price to Book Value Related Metrics
| PE Ratio | 22.42 |
| PS Ratio | 4.693 |
| PEG Ratio | 0.2210 |
| Price to Free Cash Flow | 19.50 |
| Price | 153.04 |
| Earnings Yield | 4.46% |
| Market Cap | 15.55B |
| PEGY Ratio | 0.2210 |
| Operating PE Ratio | 19.64 |
| Normalized PE Ratio | 22.88 |